Ten stocks took a beating on Wednesday, mimicking a mostly pessimistic broader market, as investors repositioned portfolios amid geopolitical and macroeconomic uncertainties. Notably, investors turned cautious amid concerns over a bubbling AI.
On Wall Street, only the Dow Jones finished in the green, inching up 0.04 percent. The S&P 500 and the tech-heavy Nasdaq dropped by 0.24 percent and 0.67 percent, respectively.
Indices aside, this article focuses on the 10 companies that led the session’s decline and breaks down the reasons behind their performance.
To compile the list, we focused exclusively on stocks with $2 billion in market capitalization and at least 5 million shares in trading volume.
A man in black suit holding a tablet looks at stock market data on a monitor. Photo by Tima Miroshnichenko on Pexels
10. Cameco Corporation (NYSE:CCJ)
Cameco Corp. extended losses to a second day on Wednesday, shedding 4.54 percent to close at $70.47 apiece, as investors appeared to be in a wait-and-see mode for updates on the geopolitical front, alongside macroeconomic uncertainties surrounding the uranium industry.
Cameco Corporation (NYSE:CCJ) dropped alongside its counterparts as investors unloaded positions while waiting for developments on the Russia-Ukraine potential ceasefire that could stamp out the possibility of sanctions on the latter’s strategic nuclear sector.
Without such sanctions, US uranium producers would remain in cut-throat competition with Russian suppliers.
Earlier this week, uranium stocks also took a beating from news that Kazakhstan—the world’s largest uranium producer—is ramping up production of uranium products.
Through KATKO, a joint venture with France’s Orano Mining, Kazakhstan is planning to scale production back up to 4,000 metric tons per year, a level it last touched in 2021 after slashing output by 2,000 tons between 2017 and 2024 due to declining uranium prices.
The higher production is expected to begin as early as next year.
9. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Recursion Pharmaceuticals dropped for a third straight day on Wednesday, slashing 6.29 percent to close at $4.77 apiece after investors mimicked the recent selling of three company executives.
In separate regulatory filings on Tuesday, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) announced that its chief executive officer (CEO), chief financial officer (CFO), and chief research and development officer (CRDO) unloaded positions in the company on August 15 and 18.
CEO Christopher Gibson, for his part, unloaded $40,390 worth of shares on August 15 at a price of $5.64. Despite the transaction, Gibson’s stake in the company remained at 954,229.
Meanwhile, CFO Ben Taylor also unloaded $11,908 worth of shares in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) on August 15 at a price of $5.64 apiece, bringing his ownership in the company to 811,226.
CRDO Najat Khan sold shares worth $3,789 at a price of $5.64 on August 15, followed by shares amounting to $36,599 at an average price of $5.524 on August 18, 2025.
All transactions represented shares that have been withheld to satisfy tax withholding and remittance obligations in connection with the net settlement of restricted stock units.
In the second quarter of the year, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) widened its net loss by 76 percent to $171.9 million from $97.5 million in the same period last year. Total revenues increased by 33 percent to $19.2 million from $14.4 million year-on-year.
Hedge Fund Resource Center